MariaDB Completes GridGain Acquisition to Power the Next Generation of Agentic AI
24.3.2026 14:00:00 CET | Business Wire | Press release
The acquisition creates the industry’s first AI-Ready Operating Platform – unifying transactions, analytics and in-memory speed to eliminate infrastructure fragmentation
MariaDB plc today announced the successful completion of its acquisition of GridGain Systems, Inc., the pioneer of in-memory computing and the force behind Apache Ignite. This strategic acquisition marks MariaDB’s move towards delivery of an AI-Ready Operating Platform, a unified system designed to handle the extreme-velocity data requirements of autonomous AI agents.
As enterprises transition from simple AI assistants to autonomous agentic systems that reason and act, traditional data layers are reaching a breaking point. By integrating GridGain’s in-memory technology, MariaDB now provides a single, high-velocity, persistent grounding layer that supports the entire AI lifecycle – from real-time data ingestion to complex reasoning.
“For the last 18 months, we have been building MariaDB for the agentic era,” said Rohit de Souza, CEO of MariaDB. “By bringing GridGain into the fold, we are delivering a unified platform that does the heavy lifting for the enterprise. We are removing the friction of manual data assembly and defining the high-velocity grounding layer that AI agents need to be truly useful – all backed by integrated support from a single company.”
Solving the Agentic Gap
The urgency for this platform is backed by industry shifts. Gartner® predicts, “40% of enterprise applications will feature task-specific AI agents by 2026 – up from less than 5% in 2025.”¹ Without a high-quality data foundation, “IDC warns that by 2027, companies that fail to establish high-quality, AI-ready data foundations will suffer a 15% productivity loss as generative and agentic systems falter” (IDC FutureScape 2026; Category: Worldwide Agentic Artificial Intelligence; Prediction 1).
MariaDB’s new platform addresses this inflection point by consolidating previously fragmented layers:
- Unified transactions & analytics: Run real-time analytics alongside live transactions on the same platform without the friction of ETL (extract, transform, load).
- In-memory velocity: Leveraging GridGain’s expertise to provide sub-millisecond response times for agentic workloads.
- Natively AI ready: Built-in vector capabilities to store, index and query embeddings, along with MCP server and integrations to AI frameworks, essential for building RAG workloads.
- Global scale: Technology to support AI deployments across hybrid and multicloud environments, with instant scaling.
The Agentic Shift: No Assembly Required
Instead of forcing developers to manually stitch together separate databases for memory, vector search and transactions, MariaDB now offers a “single pane of glass” for data. This reduces complexity, lowers total cost of ownership (TCO) and allows developers to focus on building agent logic rather than managing backend bottlenecks.
“Building for this level of scale today is like trying to build a high-speed machine out of a bucket of LEGOs – you have the pieces, but none of the pieces were meant to fit together under that kind of intensity,” said Vikas Mathur, chief product officer at MariaDB plc. “At AI-speed, the window for a response shrinks. A data platform like MariaDB no longer has seconds; it has single-digit milliseconds to deliver answers to agents. By providing a platform with a high-speed in-memory ‘baseplate’ already built-in, we eliminate the friction of manual assembly. We are giving developers a unified grounding layer that can handle the massive scale these agents demand.”
Looking Ahead: The Distributed Future
GridGain’s technology provides the foundation for the next phase of MariaDB’s evolution: a globally distributed data layer. As AI agents become autonomous and dispersed, the data they rely on must be as resilient and localized as the agents themselves. By extending the MariaDB Enterprise Platform into a distributed architecture, MariaDB ensures this grounding layer can scale across any region without sacrificing the sub-millisecond speed that machine-velocity workflows demand. This is a significant acceleration of MariaDB’s commitment to a world where machine-speed is the baseline.
A Year of Unstoppable Momentum
The completion of the GridGain acquisition is the latest milestone in a series of strategic moves to redefine the modern data stack for the AI era. Over the past 18 months, MariaDB has rapidly accelerated its innovation cycle, marked by MariaDB’s acquisitions and complete integrations last year of SkySQL (cloud/DBaaS) and Galera Cluster (high availability). MariaDB also recently launched MariaDB Enterprise Platform 2026, the industry’s first unified solution to feature native RAG-in-a-box pipelines and Model Context Protocol (MCP) support, allowing AI agents to communicate directly with enterprise data. In addition, last year the company launched MariaDB Exa, an extremely powerful analytics engine that enables near real-time analytics on transactional data without the need to ETL or move data.
This commitment to innovation has earned significant industry recognition. In the past year, MariaDB was honored with the 2025 DBTA Readers’ Choice Award for Best Overall Database and the 2025 AI TechAward for Best in Open Source AI. These accolades, combined with the introduction of native vector search and a new serverless cloud experience, solidify MariaDB’s position as the definitive high-velocity alternative to legacy database constraints.
Customer and Analyst Endorsements
“At Hatch, we ensure the timely delivery of some of the world's most complex engineering and construction projects. To manage this level of global scale, we moved beyond rigid and siloed legacy infrastructure to a data-centric platform,” said Tara Drover, CIO at Hatch. “By migrating to GridGain, we dramatically reduced our data processing times, transforming complex analysis and mid-project changes that once took minutes into near-instant outcomes. This is exactly the type of high-velocity capability we needed as we move toward an agentic future and deliver intelligent, predictive project management capabilities to our customers. We are excited to see GridGain become a foundational part of MariaDB, offering a unified platform that can support the next generation of autonomous and data-intensive workflows across the industries we serve.”
“MariaDB has been assembling a broader AI-ready platform through integrated vector search, the MariaDB Exa partnership for high-performance analytics, and the reacquisition of SkySQL to strengthen cloud delivery,” said Devin Pratt, research director, Data Management for IDC. “The GridGain acquisition extends that strategy into in-memory and real-time data processing, which may appeal to buyers seeking a more open alternative to fragmented or proprietary data stacks.”
Register for our upcoming webinar: Learn more about how MariaDB and GridGain are powering enterprise agentic AI strategies, by joining our joint webinar on April 8, 2026.
About MariaDB
MariaDB seeks to eliminate the constraints and complexity of proprietary databases, enabling organizations to reinvest in what matters most – rapidly developing innovative, customer-facing applications. Enterprises can depend on a single complete hybrid database platform for all their needs, that can be deployed in minutes for transactional, analytical, hybrid and AI use cases. Trusted by organizations such as Deutsche Bank, DBS, Nokia, Red Hat, Samsung and VirginMedia O2 – MariaDB delivers customer value without the financial burden of legacy database providers. For more information, please visit mariadb.com.
¹Gartner Press Release, Gartner Predicts 40% of Enterprise Apps Will Feature Task-Specific AI Agents by 2026, Up from Less Than 5% in 2025, August 2025, https://www.gartner.com/en/newsroom/press-releases/2025-08-26-gartner-predicts-40-percent-of-enterprise-apps-will-feature-task-specific-ai-agents-by-2026-up-from-less-than-5-percent-in-2025.
Gartner is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260324392851/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom